8-K - Kalaris Therapeutics Inc | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Kalaris Therapeutics, Inc. made available an updated corporate presentation on March 9, 2026, for use at The Leerink Partners Global Healthcare Conference and other conferences. The presentation provides updates on timelines for reporting data from the Phase 1b/2 multi-ascending dose clinical trial of TH103 and initiating Phase 3 clinical development, along with other clinical operations updates and cash runway guidance into Q4 2027.

Key Takeaways

1Updated corporate presentation dated March 9, 2026, attached as Exhibit 99.1

2Presentation for upcoming meetings at The Leerink Partners Global Healthcare Conference and other conferences

3Updates on timelines for reporting data from ongoing Phase 1b/2 multi-ascending dose clinical trial of TH103

4Updates on timelines for initiating Phase 3 clinical development of TH103

5Preliminary Phase 1b/2 data expected in 1H 2027

6$50MM oversubscribed private placement in December 2025 with investors including ADAR1 Capital Management, Coastlands Capital, Invus, RTW Investments, Samsara BioCapital, Woodline Partners LP

7Sufficient cash runway to fund company into Q4 2027

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

. Regulation FD Disclosure. On March 9, 2026, Kalaris Therapeutics, Inc. (the “Company”) made available an updated corporate presentation that it plans to use f

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Corporate Presentation, dated March 9, 2026 104 Cover Page Interactive Data File

Exhibits Only

Source Document

Exhibits (2)

8-K

99.1

EX-99.1